Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway

Journal of Applied Physiology

Volumn 99, Issue 1, 2005, Pages 71-80

  Yimlamai, Tossaporn ^a   Dodd, Stephen L ^a   Borst, Stephen E ^a,b   Park, Sooyeon ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hindlimb unweighting; Insulin like growth factor 1; Protein degradation

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLENBUTEROL; MUSCLE PROTEIN; PROTEASOME; SOMATOMEDIN C; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUGATE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FAST MUSCLE FIBER; FEMALE; IMMOBILIZATION; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; MUSCLE LEVEL; NONHUMAN; PLANTARIS MUSCLE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; SKELETAL MUSCLE; SLOW MUSCLE FIBER; SOLEUS MUSCLE; TIBIALIS ANTERIOR MUSCLE; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; CLENBUTEROL; FEMALE; GENE EXPRESSION REGULATION; HINDLIMB SUSPENSION; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 21644478996     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00448.2004     Document Type: Article

References (52)

1. Adams GR. Role of insulin-like growth factor-I in the regulation of skeletal muscle adaptation to increased load. Exerc Sport Sci Rev 26: 31-60, 1998.
2. 14k/HR6B is dispensable for increased protein catabolism in muscle of fasted mice. Am J Physiol Endocrinol Metab 283: E482-E489, 2002.
3. Agrawal S, Thakur P, and Katoch S. Beta adrenoceptor agonist, clenbuterol, and isoproterenol retard denervation atrophy in rat gastrocnemius muscle: use of 3-methylhistidine as a marker of myofibrillar degeneration. J Physiol 53: 229-237, 2003.
4. Attaix D, Aurousseau E, Combaret L, Kee A, Larbaud D, Ralliere C, Souweine B, Taillandier D, and Tilignac T. Ubiquitin-proteasome dependent proteolysis in skeletal muscle. Reprod Nutr Dev 38: 153-165, 1998.
5. Awede BL, Thissen JP, and Lebacq J. Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am J Physiol Endocrinol Metab 282: E31-E37, 2002.
6. Benson DW, Nelson TF, Chance WT, Zhang FS, James JH, and Fischer JE. Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res 50: 1-5, 1991.
7. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poieymirou WT, Panaro FJ, Na E, Dhamarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, and Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708, 2001.
8. Booth FW and Criswell DS. Molecular events underlying skeletal muscle atrophy and the development of effective countermeasures. Int J Sports Med 18: 256-269, 1997.
9. Bose S, Mason GG, and Rivett A. Phosphorylation of proteasomes in mammalian cells. Mol Biol Rep 26: 11-14, 1999.
10. Chrysis D and Underwood LE. Regulation of components of the ubiquitin system by insulin-like growth factor 1 and growth hormone in skeletal muscle of rats made catabolic with dexamethasone. Endocrinology 140: 5635-5641, 1999.
11. 2-adrenergic agonist (clenbuterol): role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 95: 2367-2372, 1995.
12. Coux O, Tanaka K, and Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65: 801-847, 1996.
13. Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochemie 83: 301-310, 2001.
14. Demartino GN and Ordway GA. Ubiquitin-proteasome pathway of intracellular protein degradation: implications for muscle atrophy during unloading. Exerc Sport Sci Rev 26: 219-252, 1998.
15. Dodd SL and Koesterer TJ. Clenbuterol attenuates muscle atrophy and dysfunction in hindlimb-suspended rats. Aviat Space Environ Med 73: 635-639, 2002.
16. Fan J, Molina PE, Gelato MC, and Lang CH. Differential tissue regulation of insulin-like growth factor-1 content and binding proteins after endotoxin. Endocrinology 134: 1685-1692, 1994.
17. Fang CH, Li BG, Tiao G, Wang JJ, Fischer JE, and Hasseigren PO. The molecular regulation of protein breakdown following burn injury is different in fast- and slow-twitch skeletal muscle. Int J Mol Med 1: 163-169, 1998.
18. Fitts RH, Riley DR, and Widrick JJ. Physiology of a microgravity environment. Invited review: Microgravity and skeletal muscle. J Appl Physiol 89: 823-839, 2000.
19. Florini JR, Ewton DZ, and Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 17: 481-517, 1996.
20. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98: 1440-1445, 2001.
21. Hayes A and Williams DA. Examining potential drug therapies for muscle dystrophy utilizing the dy/dy mouse: I. Clenbuterol. J Neurol Sci 157: 122-128, 1998.
22. Hong D and Frosberg NE. Effects of serum and insulin-like growth factor I on protein degradation and protease gene expression in rat L8 myotubes. J Anim Sci 72: 2279-2288, 1994.
23. Ikemoto M, Nikawa T, Takeda S, Watanabe C, Kitano T, Baldwin KM, Izumi R, Nonaka I, Towatari T, Teshima S, Rokutan K, and Kishi K. Space shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association with activation of ubiquitin-proteasome pathway. FASEB J 15: 1279-1281, 2001.
24. Jagoe RT and Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 4: 183-190, 2001.
25. Jaspers SR, Fagan JM, Satarug S, Cook PH, and Tischler ME. Effects of immobilization on rat hind limb muscles under non-weight-bearing conditions. Muscle Nerve 11: 458-466, 1988.
26. Koesterer TK, Dodd SL, Powers SK. Increased antioxidant capacity does not attenuate muscle atrophy caused by unweighting. J Appl Physiol 93: 1959-1965, 2002.
27. 2+-dependent and ubiquitin/proteasome-dependent proteolytic pathways in fast-twitch and slow-twitch rat muscle following hyperinsulinaemia. Clin Sci (Lond) 101: 551-558, 2001.
28. Lawler JM, Song W, and Demaree SR. Hindlimb unloading increases oxidative stress and disrupts antioxidant capacity in skeletal muscle. Free Radic Biol Med 35: 9-16, 2003.
29. Li BG, Hasseigren PO, Fang CH, and Warden GD. Insulin-like growth factor-T blocks dexamethasone-induced protein degradation in cultured myotubes by inhibiting multiple proteolytic pathways. J Burn Care Rehabil 25: 112-118, 2004.
30. Mantle D and Preedy VR. Adverse and beneficial functions of proteolytic enzymes in skeletal muscles: an overview. Adverse Drug React Toxicol Rev 21: 31-49, 2002.
31. Mason GG, Hendil KB, and Rivett A. Phosphorylation of proteasomes in mammalian cells: identification of two phosphorylated subunits and the effect of phosphorylation on activity. Eur J Biochem 238: 453-462, 1996.
32. Morey-Holton ER and Globus RK. Hindlimb unloading rodent model: technical aspects. J Appl Physiol 92: 1367-1377, 2002.
33. Navegantes L, Migliorini RH, and Kettelhut IC. Adrenergic control of protein metabolism in skeletal muscle. Curr Opin Clin Nutr Metab Care 5: 281-286, 2002.
34. Ohira Y, Yoshinaga T, Nomura T, Kawano F, Ishihara A, Roy RR, and Edgerton VR. Gravitational unloading effects on muscle fiber size, phenotype, and myonuclear number. Adv Space Res 30: 777-781, 2002.
35. Reeds PJ, Hay SM, Dorwood PM, and Palmer RM. Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. Br J Nutr 56: 249-258, 1986.
36. Riley DA, Slocum GR, Bain JL, Seldak FR, Sowa TE, and Mellender JW. Rat hindlimb unloading: soleus histochemistry, ultrastructure, and electromyography. J Appl Physiol 69: 58-66, 1990.
37. Roer RD and Dillaman RM. Decreased femoral arterial flow during simulated microgravity in the rat. J Appl Physiol 76: 2125-2129, 1994.
38. Severgnini S, Lowenthal DT, Millard WJ, Simmen FA, Pollock BH, and Borst SE. Altered IGF-1 and IGFBPs in senescent male and female rats. J Gerontol A Biol Sci Med Sci 54: 111-115, 1999.
39. Sillence MN, Matthews ML, and Badran TW. Effect of clenbuterol on growth in underfed cattle. Aust J Arg Res 51: 401-406, 2000.
40. Solomon V and Goldberg AL. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biochem 271: 26690-26697, 1996.
41. Stein RL, Melabdri F, and Dick L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 35: 3899-3908, 1996.
42. Stevens L, Firinga C, Gohlsch B, Bastide B, Meunier Y, and Pette D. Effects of unweighting and clenbuterol on myosin light and heavy chains in fast and slow muscles of rat. Am J Physiol Cell Physiol 279: C1558-C1563, 2000.
43. Sultan KR, Dittrich BT, Leisner E, Paul N, and Pette D. Fiber type-specific expression of major proteolytic enzyme system in fast- to slow-transforming rabbit muscle. Am J Physiol Cell Physiol 280: C239-C247, 2001.
44. 2+-activated and ATP-ubiquitin-dependent proteinases in the unweighted rat soleus muscle. Biochem J 316: 65-72, 1996.
45. Thomason DB and Booth FW. Atrophy of the soleus muscle by hindlimb unweighting. J Appl Physiol 68: 1-12, 1990.
46. Von Deutsch DA, Abukhalaf IK, Wineski LE, Roper RR, Aboul-Enein HY, Paulsen DF, and Potter DE. Distribution and muscle-sparing effects of clenbuterol in hindlimb-suspended rats. Pharmacology 65: 38-48, 2002.
47. Waalkes TP and Udenfriend S. A fluorometric method for the estimation of tyrosine in plasma and tissues. J Lab Clin Med 50: 733-736, 1957.
48. Wing SS and Bedard N. Insulin-like growth factor I stimulates degradation of an mRNA transcript encoding the 14kDa ubiquitin-conjugating enzyme. Biochem J 319: 455-461, 1996.
49. Wing SS, Hass AL, and Goldberg AL. Increase in ubiquitin-protein conjugates concomitant with the increase in proteolysis in rat skeletal muscle during starvation and atrophy denervation. Biochem J 307: 639-645, 1995.
50. Yang YT and McElligott MA. Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J 261: 1-10, 1989.
51. Zeman RJ, Ludermann R, Easton TG, and Etlinger JD. Slow to fast alteration in skeletal muscle fibers caused by clenbuterol. Am J Phvsiol Endocrinol Metab 254: E726-E732, 1988.
52. 2-agonist retards atrophy in denervated muscle. Am J Physiol Endocrinol Metab 252: E152-E155, 1987.